The Food and Drug Administration (FDA) has approved Recarbrio™ (imipenem, cilastatin, and relebactam; Merck) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia
The FDA has granted Priority Review to cefiderocol (Shionogi) for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.
Pfzier announced topline results from a second phase 3 trial investigating its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 to 49 years.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
Pfizer announced topline data from one of its phase 3 studies for 20-valent pneumococcal conjugate vaccine (20vPnC) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged ≥18 years. The randomized, double-blind trial included 3880 adults aged ≥18 years who were pneumococcal vaccine-naive. The trial was designed to compare…
The FDA has accepted for review a supplemental New Drug Application (sNDA) for Recarbrio™ (imipenem, cilastatin, and relebactam; Merck), to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
The FDA has requested that all manufacturers of bacitracin for injection voluntarily withdraw their product from the market.
As of Sunday, 59 people in Wuhan were being treated for the respiratory illness
The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.
Many HMOs and insurance companies now offer ‘advice lines’ where patients can speak to an on-call nurse. In this month’s case, we look at a scenario where clinicians failed to recognize the seriousness of a patient’s complaints.
